Schneider Gabriela, Kaliappan Alagammai, Nguyen Taylor Q, Buscaglia Robert, Brock Guy N, Hall Melissa Barousse, DeSpirito Crissie, Wilkey Daniel W, Merchant Michael L, Klein Jon B, Wiese Tanya A, Rivas-Perez Hiram L, Kloecker Goetz H, Garbett Nichola C
UofL Health-Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
Department of Mathematics and Statistics, Northern Arizona University, Flagstaff, AZ 86011, USA.
Cancers (Basel). 2021 Oct 23;13(21):5326. doi: 10.3390/cancers13215326.
Early detection of lung cancer (LC) significantly increases the likelihood of successful treatment and improves LC survival rates. Currently, screening (mainly low-dose CT scans) is recommended for individuals at high risk. However, the recent increase in the number of LC cases unrelated to the well-known risk factors, and the high false-positive rate of low-dose CT, indicate a need to develop new, non-invasive methods for LC detection. Therefore, we evaluated the use of differential scanning calorimetry (DSC) for LC patients' diagnosis and predicted survival. Additionally, by applying mass spectrometry, we investigated whether changes in O- and N-glycosylation of plasma proteins could be an underlying mechanism responsible for observed differences in DSC curves of LC and control subjects. Our results indicate selected DSC curve features could be useful for differentiation of LC patients from controls with some capable of distinction between subtypes and stages of LC. DSC curve features also correlate with LC patients' overall/progression free survival. Moreover, the development of classification models combining patients' DSC curves with selected plasma protein glycosylation levels that changed in the presence of LC could improve the sensitivity and specificity of the detection of LC. With further optimization and development of the classification method, DSC could provide an accurate, non-invasive, radiation-free strategy for LC screening and diagnosis.
肺癌(LC)的早期检测显著提高了成功治疗的可能性,并改善了肺癌的生存率。目前,建议对高危个体进行筛查(主要是低剂量CT扫描)。然而,近期与知名风险因素无关的肺癌病例数量增加,以及低剂量CT的高假阳性率,表明需要开发新的非侵入性肺癌检测方法。因此,我们评估了差示扫描量热法(DSC)在肺癌患者诊断和预测生存方面的应用。此外,通过质谱分析,我们研究了血浆蛋白O-糖基化和N-糖基化的变化是否可能是导致肺癌患者与对照受试者DSC曲线观察到差异的潜在机制。我们的结果表明,选定的DSC曲线特征可用于区分肺癌患者与对照,其中一些特征能够区分肺癌的亚型和阶段。DSC曲线特征还与肺癌患者的总生存期/无进展生存期相关。此外,结合患者DSC曲线与肺癌存在时发生变化的选定血浆蛋白糖基化水平建立分类模型,可提高肺癌检测的敏感性和特异性。随着分类方法的进一步优化和发展,DSC可为肺癌筛查和诊断提供一种准确、非侵入性、无辐射的策略。